You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Guidelines and Advice
Status: Current
ID: MCC
Jun 2006
Guidelines and Advice
Aug 2006
Guidelines and Advice
May 2006
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Apr 2006
Guidelines and Advice
Status: Current
ID: GL-C50-03
Apr 2006
Statistical Reports
Drug
Other Name(s): Cosmegen®
Jan 2022
Drug
Other Name(s): Xalkori®
Jan 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
ODB - General Benefit
    dexamethasone
Jan 2022

Pages